Regulatory News Improving on R-CHOP, ODAC votes 11:2 to move Genentech’s Polivy to the first line in diffuse large B-cell lymphoma March 10, 2023Vol.49 No.10By Jacquelyn Cobb
Drugs & Targets Kronos Bio & Genentech to collaborate on therapies against transcriptional targets January 13, 2023Vol.49 No.02
Drugs & Targets FDA approves updated drug labeling for Xeloda tablets under Project Renewal December 16, 2022Vol.48 No.45
Drugs & Targets Tecentriq receives FDA approval for alveolar soft part sarcoma December 16, 2022Vol.48 No.45
Drugs & Targets Genentech voluntarily withdraws U.S. indication of Tecentriq for types of bladder cancer December 02, 2022Vol.48 No.43
Drugs & Targets FDA accepts supplemental BLA for Genentech’s Polivy combination for previously untreated diffuse large B-cell lymphoma September 09, 2022Vol.48 No.32
Clinical RoundupFree Subcutaneous formulation of Tecentriq demonstrates positive phase III results August 05, 2022Vol.48 No.31
